Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

SELL
$0.89 - $2.52 $493 - $1,396
-554 Reduced 3.94%
13,509 $12,000
Q4 2022

Feb 09, 2023

BUY
$1.02 - $7.48 $14,344 - $105,191
14,063 New
14,063 $16,000

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $76.1M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.